Evolution of BCR/ABL gene mutation in CML is time dependent and dependent on the pressure exerted by tyrosine kinase inhibitor.
about
Combined HSP90 and kinase inhibitor therapy: Insights from The Cancer Genome Atlas.Opening the door to the development of novel Abl kinase inhibitors.Ultra-deep sequencing leads to earlier and more sensitive detection of the tyrosine kinase inhibitor resistance mutation T315I in chronic myeloid leukemia.Molecular screening and the clinical impacts of BCR-ABL KD mutations in patients with imatinib-resistant chronic myeloid leukemia.Membrane perturbation through novel cell-penetrating peptides influences intracellular accumulation of imatinib mesylate in CML cells.Characteristics of BCR-ABL kinase domain mutations in chronic myeloid leukemia from India: not just missense mutations but insertions and deletions are also associated with TKI resistance.
P2860
Evolution of BCR/ABL gene mutation in CML is time dependent and dependent on the pressure exerted by tyrosine kinase inhibitor.
description
2015 nî lūn-bûn
@nan
2015 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Evolution of BCR/ABL gene muta ...... by tyrosine kinase inhibitor.
@ast
Evolution of BCR/ABL gene muta ...... by tyrosine kinase inhibitor.
@en
type
label
Evolution of BCR/ABL gene muta ...... by tyrosine kinase inhibitor.
@ast
Evolution of BCR/ABL gene muta ...... by tyrosine kinase inhibitor.
@en
prefLabel
Evolution of BCR/ABL gene muta ...... by tyrosine kinase inhibitor.
@ast
Evolution of BCR/ABL gene muta ...... by tyrosine kinase inhibitor.
@en
P2093
P2860
P1433
P1476
Evolution of BCR/ABL gene muta ...... by tyrosine kinase inhibitor.
@en
P2093
Babu Rao Vundinti
Chandrakala Shanmukhaiah
Kanjaksha Ghosh
Prantar Chakrabarti
Shantashri Vaidya
P2860
P304
P356
10.1371/JOURNAL.PONE.0114828
P407
P577
2015-01-28T00:00:00Z